PL450027A1 - Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors - Google Patents

Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors

Info

Publication number
PL450027A1
PL450027A1 PL450027A PL45002724A PL450027A1 PL 450027 A1 PL450027 A1 PL 450027A1 PL 450027 A PL450027 A PL 450027A PL 45002724 A PL45002724 A PL 45002724A PL 450027 A1 PL450027 A1 PL 450027A1
Authority
PL
Poland
Prior art keywords
antibody
nucleic acid
acid molecule
car
therapy
Prior art date
Application number
PL450027A
Other languages
Polish (pl)
Inventor
Iga JANCEWICZ
Paweł Wiśniewski
Radosław Zagożdżon
Brygida BARAN
Original Assignee
4Cell Therapies Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Cell Therapies Spółka Akcyjna filed Critical 4Cell Therapies Spółka Akcyjna
Priority to PL450027A priority Critical patent/PL450027A1/en
Priority to PCT/PL2025/050077 priority patent/WO2026084605A1/en
Publication of PL450027A1 publication Critical patent/PL450027A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest przeciwciało 2A3 charakteryzujące się tym, że wykazuje wielospecyficzność wobec białek z rodziny CEACAM wybranych z grupy obejmującej CEACAM1, CEACAM3, CEACAM5, CEACAM6. Ponadto przedmiotem zgłoszenia jest cząsteczka kwasu nukleinowego kodująca przeciwciało określone w wynalazku, wektor zawierający wymienioną cząsteczkę kwasu nukleinowego oraz konstrukt CAR z wymienionym przeciwciałem. Kolejnym przedmiotem zgłoszenia jest przeciwciało 2A3 do zastosowania w terapii CAR-T do leczenia nowotworów wykazujących nadekspresję białka wybranego spośród CEACAM1, CEACAM3, CEACAM5, CEACAM6 albo jednocześnie wszystkich wymienionych.The subject of the application is the 2A3 antibody, characterized in that it exhibits multispecificity towards CEACAM family proteins selected from the group consisting of CEACAM1, CEACAM3, CEACAM5, and CEACAM6. Furthermore, the subject of the application is a nucleic acid molecule encoding the antibody defined in the invention, a vector containing said nucleic acid molecule, and a CAR construct with said antibody. Another subject of the application is the 2A3 antibody for use in CAR-T therapy for the treatment of cancers overexpressing a protein selected from CEACAM1, CEACAM3, CEACAM5, CEACAM6, or all of the above.

PL450027A 2024-10-14 2024-10-14 Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors PL450027A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL450027A PL450027A1 (en) 2024-10-14 2024-10-14 Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors
PCT/PL2025/050077 WO2026084605A1 (en) 2024-10-14 2025-10-13 Multispecific 2a3 antibody, nucleic acid molecule encoding the antibody, vector comprising the nucleic acid molecule, construct comprising a car with the antibody, and their use in car-t cell therapy for treating solid tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL450027A PL450027A1 (en) 2024-10-14 2024-10-14 Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
PL450027A1 true PL450027A1 (en) 2026-04-20

Family

ID=98011505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL450027A PL450027A1 (en) 2024-10-14 2024-10-14 Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors

Country Status (2)

Country Link
PL (1) PL450027A1 (en)
WO (1) WO2026084605A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040824A1 (en) * 2010-10-01 2012-04-05 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
WO2021059075A1 (en) * 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040824A1 (en) * 2010-10-01 2012-04-05 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
WO2021059075A1 (en) * 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANCEWICZ I. ET AL.: "Cancer Immunol Immunother. 2024 Jan 27;73(2): 30", NEW CEACAM-TARGETING 2A3 SINGLE-DOMAIN ANTIBODY-BASED CHIMERIC ANTIGEN RECEPTOR T-CELLS PRODUCE ANTICANCER EFFECTS IN VITRO AND IN VIVO. *

Also Published As

Publication number Publication date
WO2026084605A1 (en) 2026-04-23

Similar Documents

Publication Publication Date Title
Schwechheimer et al. E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas
ES2253533T3 (en) PROCEDURE FOR QUALITATIVE AND / OR QUANTITATIVE DETECTION OF CELLS.
Rong et al. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers
Bradley et al. Increased expression of the epidermal growth factor receptor on human colon carcinoma cells
Esteban et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients
Welinder et al. Primary breast cancer tumours contain high amounts of IgA1 immunoglobulin: an immunohistochemical analysis of a possible carrier of the tumour-associated Tn antigen
WO2015050107A1 (en) Method for detecting pancreatic tumor, antibody, and pancreatic tumor detection kit
EP2220505B1 (en) Methods of diagnosing cancer
Hoar et al. Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma
Bartkowiak et al. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile
Konishi et al. Notch1 directly induced CD133 expression in human diffuse type gastric cancers
Volm et al. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases
PL450027A1 (en) Multispecific antibody 2A3, a nucleic acid molecule encoding the antibody, a vector containing the nucleic acid molecule, a construct containing a CAR with the antibody, and their use in CAR-T therapy for the treatment of solid tumors
US9285371B2 (en) Method of screening antibodies with high antigen selectivity
JP2002277469A (en) Method for detecting prostate-specific membrane antigen in serum
ES2776733T3 (en) Kit comprising an antibody that specifically binds to the complement factor B protein and an antibody that specifically binds to the protein of carbohydrate antigen 19-9 for the diagnosis of pancreatic cancer
US6759204B2 (en) Method and kit for early diagnosis of cancer
AU2016367349B2 (en) Marker for pancreatic cancer and intraductal papillary mucinous neoplasms
GHAFARZADEGAN et al. HER2/NEN EXPRESSION IN COLON ADENOCARCINOMA AND ITS CORRELATION WITH CLINICOPATHOLOGIC VARIABLES
Shimo et al. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma
CN103562722A (en) A method of differentiating oncogenic changes of the thyroid, a kit to embody the method and the use of metallothionein (mt) for differentiating oncogenic changes of the thyroid
CN101836115A (en) Use of tenascin-W as a biomarker for colon cancer
TWI780067B (en) Monoclonal antibodies against MELK and their uses
Qi et al. Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips
Chigira et al. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas